{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:19:50Z","timestamp":1770992390545,"version":"3.50.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T00:00:00Z","timestamp":1301443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3,30]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Anti-neutrophil cytoplasmic antibodies (ANCA) have been associated with a spectrum of vasculitis that includes granulomatous polyangiitis (formerly known as Wegener's granulomatosis), microscopic polyangiitis, the Churg\u2013Strauss syndrome, primary pauciimmune necrotizing and crescentic glomerulonephritis and related forms of vasculitis. In vitro, in vivo and clinical evidence support the conclusion that ANCA participate in the pathophysiology of this disease spectrum. Rituximab is a potent tool that can interrupt B cell-mediated immunity without major compromise of T cell-mediated immunity. Thus, it has great appeal as a tool to interrupt antibody-mediated autoimmune disease. The results of two prospective randomized trials confirm that rituximab can be effective as part of induction therapy for active ANCA-associated vasculitis. The safety profile for rituximab appears favourable relative to cyclophosphamide and steroids. However, there remain many patients who require individualized adjustments of ancillary therapy, as breakthrough disease, relapses and infectious complications do occur. Based on our current knowledge, rituximab should now be incorporated as part of induction therapy in many patients with ANCA-associated vasculitis. However, more work is needed to determine how rituximab may best be integrated into the overall immunosuppression of these patients.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2011.04363.x","type":"journal-article","created":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T10:48:54Z","timestamp":1301482134000},"page":"27-30","source":"Crossref","is-referenced-by-count":22,"title":["Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis"],"prefix":"10.1093","volume":"164","author":[{"given":"J","family":"Niles","sequence":"first","affiliation":[{"name":"Massachusettes General Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,3,30]]},"reference":[{"key":"2021122708481059400_b1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00005792-197311000-00002","article-title":"Wegener's granulomatosis: studies in eighteen patients and a review of the literature","volume":"52","author":"Fauci","year":"1973","journal-title":"Medicine (Balt)"},{"key":"2021122708481059400_b2","first-page":"1584","article-title":"Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies","volume":"28","author":"Choi","year":"2001","journal-title":"J Rheumatol"},{"key":"2021122708481059400_b3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1523-1755.2003.00821.x","article-title":"Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis","volume":"63","author":"Han","year":"2003","journal-title":"Kidney Int"},{"key":"2021122708481059400_b4","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1001\/archinte.1989.00390110055012","article-title":"Association between active Wegener's granulomatosis and anticytoplasmic antibodies","volume":"149","author":"Tervaert","year":"1989","journal-title":"Arch Intern Med"},{"key":"2021122708481059400_b5","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2021122708481059400_b6","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1073\/pnas.87.11.4115","article-title":"Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro","volume":"87","author":"Falk","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122708481059400_b7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1189\/jlb.1202611","article-title":"Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies","volume":"74","author":"Rarok","year":"2003","journal-title":"J Leukoc Biol"},{"key":"2021122708481059400_b8","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/1529-0131(200006)43:6<1337::AID-ANR16>3.0.CO;2-M","article-title":"Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion","volume":"43","author":"Radford","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2021122708481059400_b9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","author":"Schreiber","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2021122708481059400_b10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11926-010-0138-6","article-title":"Pathophysiology of ANCA-associated small vessel vasculitis","volume":"12","author":"Kallenberg","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"2021122708481059400_b11","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest"},{"key":"2021122708481059400_b12","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1681\/ASN.2006070718","article-title":"Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies","volume":"17","author":"Schreiber","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2021122708481059400_b13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9440(10)62951-3","article-title":"The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies","volume":"167","author":"Xiao","year":"2005","journal-title":"Am J Pathol"},{"key":"2021122708481059400_b14","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"van der Kolk","year":"2002","journal-title":"Blood"},{"key":"2021122708481059400_b15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2021122708481059400_b16","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2021122708481059400_b17","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/kel393","article-title":"Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs","volume":"46","author":"Popa","year":"2007","journal-title":"Rheumatology (Oxf)"},{"key":"2021122708481059400_b18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2021122708481059400_b19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021122708481059400_b20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"van Vollenhoven","year":"2010","journal-title":"J Rheumatol"},{"key":"2021122708481059400_b21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-6143.2008.02499.x","article-title":"Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients","volume":"9","author":"Kamar","year":"2009","journal-title":"Am J Transplant"},{"key":"2021122708481059400_b22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122708481059400_b23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122708481059400_b24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.semarthrit.2008.01.001","article-title":"Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab","volume":"38","author":"Fleischmann","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"2021122708481059400_b25","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","article-title":"A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"60","author":"Jones","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021122708481059400_b26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","article-title":"Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial","volume":"173","author":"Keogh","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2021122708481059400_b27","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2215\/CJN.08821209","article-title":"Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"5","author":"Rhee","year":"2010","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2011.04363.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/164\/Supplement_1\/27\/41909430\/j.1365-2249.2011.04363.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/164\/Supplement_1\/27\/41909430\/j.1365-2249.2011.04363.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:25:49Z","timestamp":1641054349000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/164\/Supplement_1\/27\/6438902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,30]]},"references-count":27,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2011,3,30]]},"published-print":{"date-parts":[[2011,3,30]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2011.04363.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,5]]},"published":{"date-parts":[[2011,3,30]]}}}